|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 6, No. 4, 2010, pp. 573-574
|
Bioline Code: cr10142
Full paper language: English
Document type: Case Report
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 6, No. 4, 2010, pp. 573-574
en |
Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation
Arroyo, Patricia Araque; Perez, Ruth Ubago; Feijoo, Maria Amalia Fernandez & Hernandez, Miguel Angel Calleja
Abstract
A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle of neoadjuvant chemotherapy with epirubicin and oxaliplatin. A full recovery was achieved after treatment with dexrazoxane (Cardioxane® ). This is the first time in our hospital that extravasation of an anthracycline has been treated with dexrazoxane. We used Cardioxane® , approved for the prevention of anthracycline-induced cardiotoxicity, while Savene® is indicated for the treatment of anthracycline extravasation. The treatment was effective, and the selection of Cardioxane® (seven-fold cheaper than Savene® ) yielded a cost saving. Consequently, Cardioxane® has been included in our guidelines for anthracycline extravasation.
Keywords
Anthracycline, chemotherapy, cost, dexrazoxane, extravasation
|
|
© Copyright 2010 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|